J Calvin Coffey,Kevin G Byrnes,Dara John Walsh et al.
J Calvin Coffey et al.
Over the past 5 years, systematic investigation of the mesenteric organ has expanded and shown that the mesentery is the organ in and on which all abdominal digestive organs develop and remain connected to. In turn, this observation has cla...
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial [0.03%]
预防性内镜夹在右结肠内镜黏膜切除术后临床显著出血中的作用：单中心随机对照试验
Sunil Gupta,Mayenaaz Sidhu,Neal Shahidi et al.
Sunil Gupta et al.
Background: Endoscopic mucosal resection (EMR) is a cornerstone in the management of large (≥20 mm) non-pedunculated colorectal polyps. Clinically significant post-EMR bleeding occurs in 7% of cases and is most frequentl...
Randomized Controlled Trial
The lancet. Gastroenterology & hepatology. 2022 Feb;7(2):152-160. DOI:10.1016/S2468-1253(21)00384-8 2022
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial [0.03%]
ETROLIZUMAB作为先前接受过肿瘤坏死因子抑制剂治疗的溃疡性结肠炎诱导和维持治疗的III期随机对照试验（HICKORY）
Laurent Peyrin-Biroulet,Ailsa Hart,Peter Bossuyt et al.
Laurent Peyrin-Biroulet et al.
Background: Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with modera...
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study [0.03%]
艾托利珠单抗对比英夫利昔单抗治疗中重度活动性溃疡性结肠炎（GARDENIA）：一项随机、双盲、安慰剂对照、三期研究
Silvio Danese,Jean-Frederic Colombel,Milan Lukas et al.
Silvio Danese et al.
Background: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to s...
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study [0.03%]
在中度至重度活动性溃疡性结肠炎患者中使用Etrolizumab进行维持治疗（LAUREL）：一项随机、安慰剂对照、双盲、三期研究
Severine Vermeire,Peter L Lakatos,Timothy Ritter et al.
Severine Vermeire et al.
Background: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to s...
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials [0.03%]
中度至重度活动性溃疡性结肠炎诱导治疗中etrolizumab与adalimumab或安慰剂的对比（ Hibiscus）：两项三期随机对照试验
David T Rubin,Iris Dotan,Aaron DuVall et al.
David T Rubin et al.
Background: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately...
Manasi Agrawal,Bram Verstockt
Manasi Agrawal
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium [0.03%]
治疗 pouchitis，克罗恩病，cuffitis 和其他囊袋的炎症疾病：国际回肠囊联盟共识指南
Bo Shen,Gursimran S Kochhar,David T Rubin et al.
Bo Shen et al.
Pouchitis, Crohn's disease of the pouch, cuffitis, polyps, and extraintestinal manifestations of inflammatory bowel disease are common inflammatory disorders of the ileal pouch. Acute pouchitis is treated with oral antibiotics and chronic p...
Fadi H Mourad,Jana G Hashash
Fadi H Mourad